Fund Evaluator:
State Street® SPDR® S&P® Biotech ETF (XBI)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$76.612
NAV (as of Oct 07)
$0.00
Minimum Initial
0.35% A
Expense Ratio
$10,734 Mil
Assets
Open
Status
na
12b-1 Fee
0.36%
TTM Yield
0.00%
Max Load
43%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 77.3% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 77.1% | Fidelity Advisor Biotechnology I (FBTIX) |
| 71.4% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 71.0% | Fidelity Select Biotechnology (FBIOX) |
| 58.4% | Rydex Biotechnology Inv (RYOIX) |
Data as of 6/30/2026
15.8% A
1-Mo Return
24.0% A
3-Mo Return
29.8% A
YTD Return
91.7% A
1-Yr Return
24.1% A
3-Yr Return
3.3% C
5-Yr Return
1.28 F
Category Risk Index
2.10
Total Risk Index
Fund Details
Fund Family
State Street Investment Management
Inception Date
1/31/2006
Share Class Type
Equity Investment Style
Small-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
Yes
Benchmark Index
S&P 500 (TR) (1970): 100%
Additional Fund Details
State Street® SPDR® S&P® Biotech ETF Overview
XBI Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| XBI Return (NAV) | 15.8% | 24.0% | 91.7% | 24.1% | 3.3% | 11.5% |
| XBI Grade | A | A | A | A | C | A |
| +/- Category | 7.4% | 12.1% | 58.1% | 13.2% | -1.9% | 1.4% |
| Health Avg | 8.4% | 11.9% | 33.6% | 11.0% | 5.2% | 10.0% |
| XBI Tax Cost Ratio | na | na | 0.2% | 0.1% | 0.1% | 0.1% |
XBI Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| XBI Return (NAV) | 29.8% | 35.8% | 1.1% | 7.5% | -25.8% | -20.5% | 48.2% | 32.2% | -14.9% | 43.7% | -15.4% |
| XBI Grade | A | A | C | A | D | F | A | A | F | A | D |
| +/- Category | 22.3% | 15.2% | -1.4% | 1.9% | -16.4% | -29.3% | 23.7% | 3.8% | -15.3% | 20.3% | -4.5% |
| Health Avg | 7.5% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 25.5% |
| Total Risk Index: | 2.10 - High |
| Category Risk Index: | 1.28 - High |
| Category Risk Grade: | F (89% Rank) |
| Beta: | 1.10 |
| R-Squared: | 30% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Small-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.4% |
| Dividend Distribution: | Quarterly |
| Cap Gains Distribution: | Annually |
| Total Assets: | $10734 Mil |
| Fund Total Assets: | $10,735 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 43% |
Management Team
| Number of Managers: 3 | |||
| Longest Tenure: 11.7 years | |||
| Average Tenure: 7.3 years | |||
| Managers (Year): Schneider Karl (2014), Donofrio Raymond (2017), Rabinovich Emiliano (2025) | |||
Portfolio Composition (as of 6/30/26)
| # of Holdings: | 159 |
| % in Top 10 Holdings: | 13.3% |
| Fund is Non-Diversified: | No |
| % in Foreign Issues: | 3.3% |
Portfolio Allocation |
|
| Domestic Stock: | 96.6% |
| Foreign Stock: | 3.3% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.0% |
Purchase Information
| Fund Family: | State Street Investment Management |
| Phone Number: | 866-787-2257 |
| Website: | www.spdrs.com |
| Status: | Open |
| Inception Date: | January 31, 2006 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 0.35% ( Rating : Below Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | State Street® SPDR® S&P® Biotech ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.